



January 8, 2026

National Stock Exchange of India Limited  
Exchange Plaza,  
Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 051

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

**Sub: Intimation of Earnings Conference Call for Investors/ Analysts for Q3 & 9M FY26**

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find attached the invite of the Earnings Conference Call for Investors/ Analysts to be held on Friday, January 30, 2026, at 4:00 P.M. (IST) to discuss the financial and operating performance for Q3 & 9M FY26.

We request you to kindly take the same on record.

Thanking You,

Yours faithfully,

**For Dr. Lal PathLabs Limited**

**Vinay Gujral**  
**Company Secretary & Compliance Officer**

*Encl.: As above*

## Q3 & 9M FY26 Earnings Conference Call

### Friday, January 30, 2026 at 4:00pm IST

**Gurugram, January 08, 2026:**

**Dr. Lal PathLabs Ltd. (DLPL)** will be hosting a conference call to discuss its Q3 & 9M FY26 results. DLPL will be represented by (Hony) Brig. Dr. Arvind Lal – Executive Chairman, Mr. Shankha Banerjee – Chief Executive Officer and Mr. Ved Prakash Goel – Group Chief Financial Officer & CEO – International Business.

The conference call will be initiated with a brief discussion by the management on Q3 & 9M FY26 financial and operating performance, which will be announced on the same day. Following this, there will be an opportunity for participants to get their queries addressed during the call.

**Details of the conference call are as follows:**

Time	<ul style="list-style-type: none"> <li>• 4:00pm IST on Friday, January 30, 2026</li> </ul>
Pre-registration	<p>To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.</p> <div style="display: flex; align-items: center; justify-content: space-between;"> <div style="flex: 1;">  </div> <div style="flex: 1; text-align: right;"> <a href="#" style="color: inherit; text-decoration: none;">Click here to ExpressJoin the Call</a> </div> </div> <p>You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode &amp; pin to connect to call.</p>
Universal Access	<ul style="list-style-type: none"> <li>• <b>+91 22 6280 1141</b></li> <li>• <b>+91 22 7115 8042</b></li> </ul>
Conference dial-in International Toll Number	<ul style="list-style-type: none"> <li>• <b>USA – 18667462133</b></li> <li>• <b>UK – 08081011573</b></li> <li>• <b>Singapore – 8001012045</b></li> <li>• <b>Hong Kong – 800964448</b></li> </ul>

**-ENDS-**

## About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India's leading consumer healthcare brands in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 385 test panels, 3,172 pathology tests and 1,455 radiology and cardiology tests as on March 31, 2025.

As on March 31, 2025, DLPL's has 298 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata, Bangalore & Mumbai), 6,607 Patient Service Centers (PSCs) and 12,365 Pick-up Points (PUPs). In FY25 & FY24, DLPL collected and processed approximately 86 million samples and 78 million samples from 28.8 million and 27.6 million patients, respectively.

Additional information on Dr. Lal PathLabs Limited:

Corporate Identification No: L74899DL1995PLC065388

Website: <https://www.lalpathlabs.com/>

### For further information, please contact:

Ved P Goel  
Dr. Lal PathLabs Limited  
E-mail: [ved.goel@lalpathlabs.com](mailto:ved.goel@lalpathlabs.com)

Siddharth Rangnekar / Nishid Solanki  
CDR India  
Email: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)  
[nishid@cdr-india.com](mailto:nishid@cdr-india.com)

***Disclaimer:** Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like Government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Dr. Lal PathLabs Limited will not be in any way responsible for any action taken based on such statements and discussions and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*